Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Lutathera Improves PFS in Progressive Neuroendocrine Pancreatic Tumors

January 13th 2023

The use of peptide receptor radionuclide therapy with lutetium Lu 177 dotatate improved progression-free survival in patients with unresectable, progressive neuroendocrine pancreatic tumors.

Treatment Paradigm of Advanced HCC Displays Exciting Growth in the First and Later Lines

January 13th 2023

Leading experts in the field of liver cancer contextualized how recent data are influencing the treatment paradigm in hepatocellular carcinoma.

FDA Grants Orphan Drug Designation to QN-302 for Pancreatic Cancer

January 12th 2023

The FDA has granted an orphan drug designation to QN-302 for the treatment of patients with pancreatic cancer.

Immune Checkpoint Inhibitors in HCC

January 12th 2023

A multidisciplinary panel discusses use of immune checkpoint inhibitors in patients with advanced HCC.

The Advent of Systemic Therapy for HCC

January 12th 2023

Drs Singal and Lewandowski review use of tyrosine kinase inhibitors, sorafenib and lenvatinib, and discuss trials that combined systemic therapy with chemoembolization.

Japan Approves Durvalumab/Tremelimumab Combo for HCC and Advanced NSCLC

January 6th 2023

Japan has approved durvalumab monotherapy and durvalumab plus tremelimumab for unresectable hepatocellular carcinoma, durvalumab plus tremelimumab and chemotherapy for unresectable, advanced, or recurrent non–small cell lung cancer, and durvalumab plus chemotherapy for curatively unresectable biliary tract cancer.

Mitazalimab Plus mFOLFIRINOX Delivers High ORR in Previously Untreated Metastatic Pancreatic Cancer

January 5th 2023

Adding mitazalimab to mFOLFIRINOX led to a 52% objective response rate as frontline therapy in 23 patients with metastatic pancreatic cancer.

Therapy for Locally Advanced HCC

January 5th 2023

Experts in hepatocellular carcinoma discuss treatment options for locally advanced disease.

Child-Pugh Scoring System and Liver Function Assessment

January 5th 2023

Dr Singal reviews the Child-Pugh scoring system, then Dr Lewandowski discusses the importance of considering liver function as well as disease burden when selecting a treatment strategy.

HAIC-Administered FOLFOX Lengthens DFS and Provides a Tolerable Safety Profile in HCC

January 5th 2023

Patients with hepatocellular carcinoma with microvascular invasion who received FOLFOX through hepatic arterial infusion chemotherapy experienced improved disease-free survival rates compared with those who received no adjuvant treatment.

Second-line Ripretinib Provides Clinical Benefit in GIST Harboring Mutations in KIT Exon 11 and 17/18

January 4th 2023

Ripretinib improved progression-free survival, objective response rate, and overall survival over sunitinib when given as second-line treatment to patients with gastrointestinal stromal tumor harboring mutations in KIT exon 11 and 17/18 only and who received prior imatinib.

FDA Grants Breakthrough Device Designation to OverC Multi-Cancer Detection Blood Test

January 4th 2023

The FDA has granted a breakthrough device designation to the OverC Multi-Cancer Detection Blood Test for the early detection of cancers including esophageal, liver, lung, ovarian, and pancreatic in adults aged to 50 to 75 years with average risk.

PDS0101-Based Triplet Produces Prolonged OS in Refractory HPV+ Cancers

January 3rd 2023

Treatment with PDS0101 plus the tumor-targeting IL-12 fusion protein M9241 and bintrafusp alfa elicited encouraging overall survival data in patients with checkpoint inhibitor–naïve and –refractory advanced human papillomavirus–positive anal, cervical, head and neck, vaginal, and vulvar cancer.

The Desire to Always Do More

December 29th 2022

Jaffer A. Ajani, MD, has an unyielding drive that has resulted in breakthroughs in a deadly, but often overlooked, disease.

Review of Curative Treatment Strategies for HCC

December 22nd 2022

The panel shares insight as to which patients might be candidates for curative therapies such as embolization techniques and liver transplant.

Overview of Hepatocellular Carcinoma Risk Factors

December 22nd 2022

Ghassan Abou-Alfa, MD leads Robert Lewandowski, MD, FSIR, and Amit Singal, MD in a discussion of the main risk factors for hepatocellular carcinoma.

Zanidatamab Elicits Responses in Previously Treated HER2-Amplified Biliary Tract Cancers

December 20th 2022

Zanidatamab monotherapy produced responses in previously treated patients with HER2-amplified and -expressing biliary tract cancers.

European Commission Approves Trastuzumab Deruxtecan in Pretreated HER2+ Advanced Gastric/GEJ Cancer

December 19th 2022

The European Commission has approved fam-trastuzumab deruxtecan-nxki as monotherapy for the treatment of patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.

Frontline Zolbetuximab Plus CAPOX Meets PFS, OS End Points in Claudin 18.2+ Gastric or GEJ Cancers

December 16th 2022

The addition of zolbetuximab to capecitabine and oxaliplatin resulted in a statistically significant improvement in progression-free survival and overall survival vs placebo/CAPOX in patients with Claudin 18.2–positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal cancers, meeting the primary and secondary end points of the phase 3 GLOW trial.

FDA Approves Updated Labeling for Capecitabine Tablets

December 15th 2022

The FDA has approved updated labeling for capecitabine tablets (Xeloda) under an initiative aimed to ensure labeling information is clinically meaningful and scientifically up to date.